Triple Non-Statin Therapy with Ezetimibe, Inclisiran, and Bempedoic Acid in Patients with Genetically Confirmed Statin-Induced Rhabdomyolysis: A Dual Case Report

<b>Background:</b> Statin intolerance is a serious therapeutic dilemma in secondary cardiovascular prevention (e.g., ESC/EAS Guidelines 2023). This is especially true when confirmed by genetic predisposition and complicated by rhabdomyolysis. Although several non-statin agents have become available...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jozef Dodulík, Jiří Plášek, Ivana Kacířová, Romana Uřinovská, Jiří Vrtal, Jan Václavík
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2025-05-01
coleção:	Pharmaceuticals
Assuntos:	statin intolerance rhabdomyolysis inclisiran bempedoic acid ezetimibe genetic testing
Acesso em linha:	https://www.mdpi.com/1424-8247/18/6/818
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!